[1] Liu X P, Pang Y J, Zhu W W, Zhao T T, Zheng M, Wang Y B, Sun Z J, Sun S J. Benazepril, an angiotensin-converting enayme inhibitor, alleviates renal injury in spontaneously hyperitensive rats by inhibiting advanced glycation end-product-mediated pathways[J]. Clin Expe Pharmacol P, 2009, 36:287-296. [2] Hisashi M, Hidekazu K, Toshifumi W, Hitoshi K, Masakazu N, Keita K, Jonathan N. K. Evaluation of the clinical efficacy of Benazepril in the treatment of chronic renal insufficiency in cats[J] .J Vet Intern Med, 2006, 20:1074–1079. [3] Sent U, Gossl R, Elliott J, Syme H M, Zimmering T. Comparison of efficacy of long-term oral treatment with telmisartan and Benazepril in cats with chronic kidney disease[J]. J Vet Intern Med, 2015,29(6):1479-1487. [4] Kelers K, Devi J L, Anderson G A, Zahra P, Vine J H, Whittema T. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product [J]. Aust Vet Assoc.2013, 91(8):312-319. [5]王晓华,何杏容. 金水宝联合贝那普利治疗糖尿病肾病蛋白尿的临床效果分析[J].中国医院用药评价与分析,2015,15(7):857-859. [6]国家食品药品临督管理局.标准:YBH01662005. [7] 国家食品药品临督管理局.国家药品标准:新药转正标准:第45册[S].WS1-(X-347)-2003Z. [8] 国家食品药品临督管理局.标准: YBH13652004. [9] 国家食品药品临督管理局.标准:YBH10332005. [10] 国家食品药品临督管理局.标准(试行):YBH05862004. [11]邬伟魁,严倩茹. 超高效液相色谱法在药物有关物质分析中的应用[J].中国药物评价,2015,32(3) :277-279. [12]杜小英,马东卫,宋愿智. HPLC法测定贝那普利氢氯噻嗪片有的关物质 [J].西北药学杂志,2016 (2) :149-154. [13]张祖峰,王晓红,郝晓慧等. 3种血管紧张素转换酶抑制药对急性心肌梗死患者心室重构的改善作用[J].中国药房,2018,29(4) :526-530. [14]陈攀,白雪. 贝那普利联合羟苯磺酸钙辅助胰岛素治疗老年早期糖尿病肾病的临床观察[J].中国药房,2017,28(3) :347-350. [13] 朱春玲,胡春芳,王代宏等.脉络宁注射液联合贝那普利治疗慢性肾小球肾炎的临床观察[J].中国药房,2017,27(20) :2801-2803. [15] 吕爱玲,安民民,阮爱兵等. 西格列汀联合贝那普利治疗糖尿病肾病的临床观察 [J].中国药房,2017,28(5) :646-648.
|